<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01242514</url>
  </required_header>
  <id_info>
    <org_study_id>D4300C00005</org_study_id>
    <secondary_id>2010-020892-22</secondary_id>
    <nct_id>NCT01242514</nct_id>
  </id_info>
  <brief_title>Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)</brief_title>
  <acronym>OSKIRA-X</acronym>
  <official_title>(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long term safety and tolerability of
      fostamatinib in patients with rheumatoid arthritis (RA).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to
    Rigel Pharmaceuticals.
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Who Had at Least 1 Adverse Event in Any Category</measure>
    <time_frame>Entry in extension to end of study (variable duration; maximum 109 weeks)</time_frame>
    <description>AE = adverse event, bid = twice daily, IP = investigational product, qd = once daily, SAE = serious adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean DAS28-CRP Score</measure>
    <time_frame>Weeks 0, 12, 24, 36 and 52</time_frame>
    <description>DAS28-CRP: Disease Activity Score based on a count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (CRP) and the patient's own assessment. Scores can take any positive value with a lower value indicating a better clinical condition. Number of participants are those with data at entry to this study (Week 0). As no imputation was applied, the numbers at subsequent visits are lower. bid = twice daily, CRP = C-reactive protein, qd = once daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean mTSS Score</measure>
    <time_frame>Weeks 0 and 52</time_frame>
    <description>mTSS: modified total sharp score, a measure of structural progression based upon X-rays. Hand and foot joints are scored for erosions and joint space narrowing and the results summed to give a value between 0 and 488. A higher value represents more serious progression of the disease. Number of participants are those with data at entry to this study (Week 0). As no imputation was applied, the numbers at subsequent visits are lower. bid = twice daily, N/A = not applicable, qd = once daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean HAQ-DI Score</measure>
    <time_frame>Weeks 0, 12, 24, 36 and 52</time_frame>
    <description>HAQ-DI: Health Assessment Questionnaire - Disability Index, a measure of physical function. The HAQ-DI score is then calculated by summing the category scores from 8 sub-categories (ie, scores for patient ability in dressing and grooming, rising, eating, walking, hygiene, reach, grip and common daily activities) and dividing by the number of categories completed. The HAQ-DI score takes values between 0 and 3, with a higher score indicating greater disability. Number of participants are those with data at entry to this study (Week 0). As no imputation was applied, the numbers at subsequent visits are lower. bid = twice daily, qd = once daily</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1917</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Fostamatinib 100mg twice daily</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Fostamatinib 150mg once daily</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Fostamatinib 100mg once daily</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have successfully completed a qualifying study (D4300C00001, D4300C00002,
             D4300C00003 or D4300C00004) with fostamatinib

          -  Patients who have participated in a qualifying study and who have been classified as
             non-responders due to pre-defined lack of efficacy at Week 12 (D4300C00001,
             D4300C00002, D4300C00003).

        Exclusion Criteria:

          -  Premature withdrawal from the qualifying study (D4300C00001, D4300C00002, D4300C00003
             and D4300C00004)

          -  Females who are pregnant or breast feeding

          -  Poorly controlled hypertension

          -  Significant liver function test abnormalities or physical symptoms of hepatotoxicity

          -  Significant infection

          -  Gastrointestinal intolerance

          -  Cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris O'Brien, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tavares</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zephyr Hills</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canton</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Clair Shores</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eagan</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond Heights</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olean</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Research Triangle Park</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mayfield Village</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waxford</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hixson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <state>Caba</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autonoma Bs As</city>
        <state>CBA</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <state>CRD</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>TUC</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autonoma Bs As</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quilmes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cairns</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gilly</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Recife</city>
        <state>PE</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevlievo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bowmanville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pointe-claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trois-rivieres</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osorno</city>
        <state>X Region</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucaramanga</city>
        <state>Santander</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruntal</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ceska Lipa</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hlucin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hostivice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kladno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liberec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava - Trebovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sokolov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Terezin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orleans Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halle</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bekescsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mako</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sopron</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szentes</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg-pozva</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Secunderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gandhinagar</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Udupi</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharshtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kfar-saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ramat-gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jesi</city>
        <state>AN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liepaja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siauliai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexicali</city>
        <state>Baja California</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saltillo</city>
        <state>Coahuila</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <state>JAL</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <state>NL</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obrergon</city>
        <state>SON</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pueblo Libre</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Borja</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Isidro</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chelm Slaski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kalisz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zyrardow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ploiesti</city>
        <state>Prahova</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Braila</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sankt-peterburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Niska Banja</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poprad</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rimavska Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruzomberok</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trnava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Panorama</city>
        <state>Cape Town</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Elizabeth</city>
        <state>E Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kempron Park</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stellenbosch</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Merida</city>
        <state>Extremadura</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lugansk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lutsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Simferopol</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporyzhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bracknell</city>
        <state>Berkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warrington</city>
        <state>Cheshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maidstone</city>
        <state>Kent</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eastbourne</city>
        <state>Sussex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Solihull</city>
        <state>West Midlands</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Basingstoke</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Christchurch</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ipswich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stoke on Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westcliff-on-the Sea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2010</study_first_posted>
  <results_first_submitted>December 18, 2013</results_first_submitted>
  <results_first_submitted_qc>February 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2014</results_first_posted>
  <last_update_submitted>February 25, 2014</last_update_submitted>
  <last_update_submitted_qc>February 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>OSKIRA</keyword>
  <keyword>Fostamatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total of 1917 enrolled patients: 1346, 357 &amp; 214 were allocated to the 100 mg twice daily (bid), 150 mg once daily (qd) and 100 mg qd groups, respectively (1343, 357 &amp; 212 received at least 1 dose of investigational product). As this was a long-term extension study no specific end date was given. As such no patients were recorded as completers.</recruitment_details>
      <pre_assignment_details>A total of 5 patients did not receive treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fostamatinib 100 mg Bid</title>
          <description>Oral treatment</description>
        </group>
        <group group_id="P2">
          <title>Fostamatinib 150 mg qd</title>
          <description>Oral treatment</description>
        </group>
        <group group_id="P3">
          <title>Fostamatinib 100 mg qd</title>
          <description>Oral treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1343">Patients who received treatment</participants>
                <participants group_id="P2" count="357">Patients who received treatment</participants>
                <participants group_id="P3" count="212">Patients who received treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled But Did Not Receive Treatment</title>
              <participants_list>
                <participants group_id="P1" count="3">Other</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2">Adverse event/other</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Due to project closure.</participants>
                <participants group_id="P2" count="0">Due to project closure.</participants>
                <participants group_id="P3" count="0">Due to project closure.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1343"/>
                <participants group_id="P2" count="357"/>
                <participants group_id="P3" count="212"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>e.g., project closure</title>
              <participants_list>
                <participants group_id="P1" count="1042"/>
                <participants group_id="P2" count="305"/>
                <participants group_id="P3" count="171"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject decision</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe non-compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of therapeutic response</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dev. of study specific discont. criteria</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fostamatinib 100 mg Bid</title>
          <description>Oral treatment</description>
        </group>
        <group group_id="B2">
          <title>Fostamatinib 150 mg qd</title>
          <description>Oral treatment</description>
        </group>
        <group group_id="B3">
          <title>Fostamatinib 100 mg qd</title>
          <description>Oral treatment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1343"/>
            <count group_id="B2" value="357"/>
            <count group_id="B3" value="212"/>
            <count group_id="B4" value="1912"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="12.0"/>
                    <measurement group_id="B2" value="53" spread="11.6"/>
                    <measurement group_id="B3" value="53" spread="11.3"/>
                    <measurement group_id="B4" value="53" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1086"/>
                    <measurement group_id="B2" value="297"/>
                    <measurement group_id="B3" value="193"/>
                    <measurement group_id="B4" value="1576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1092"/>
                    <measurement group_id="B2" value="278"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="1511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indian or Pakistani</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Mean DAS28-CRP Score</title>
        <description>DAS28-CRP: Disease Activity Score based on a count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (CRP) and the patient's own assessment. Scores can take any positive value with a lower value indicating a better clinical condition. Number of participants are those with data at entry to this study (Week 0). As no imputation was applied, the numbers at subsequent visits are lower. bid = twice daily, CRP = C-reactive protein, qd = once daily</description>
        <time_frame>Weeks 0, 12, 24, 36 and 52</time_frame>
        <population>The full analysis set includes those patients who received at least 1 dose of investigational product, and were summarised according to treatment first received in this study (intention-to-treat principle).</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 100 mg Bid</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 150 mg qd</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O3">
            <title>Fostamatinib 100 mg qd</title>
            <description>Oral treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Mean DAS28-CRP Score</title>
          <description>DAS28-CRP: Disease Activity Score based on a count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (CRP) and the patient's own assessment. Scores can take any positive value with a lower value indicating a better clinical condition. Number of participants are those with data at entry to this study (Week 0). As no imputation was applied, the numbers at subsequent visits are lower. bid = twice daily, CRP = C-reactive protein, qd = once daily</description>
          <population>The full analysis set includes those patients who received at least 1 dose of investigational product, and were summarised according to treatment first received in this study (intention-to-treat principle).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1247"/>
                <count group_id="O2" value="336"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=1247, 336, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="1.58" lower_limit="0.23" upper_limit="0.90"/>
                    <measurement group_id="O2" value="3.8" spread="1.24" lower_limit="0.14" upper_limit="0.84"/>
                    <measurement group_id="O3" value="3.9" spread="1.27" lower_limit="-0.12" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=1018, 288, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.34"/>
                    <measurement group_id="O2" value="3.6" spread="1.19"/>
                    <measurement group_id="O3" value="3.7" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=800, 230 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.30"/>
                    <measurement group_id="O2" value="3.7" spread="1.24"/>
                    <measurement group_id="O3" value="3.6" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=581, 148, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.32"/>
                    <measurement group_id="O2" value="3.7" spread="1.24"/>
                    <measurement group_id="O3" value="3.9" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=290, 28, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.25"/>
                    <measurement group_id="O2" value="3.8" spread="1.37"/>
                    <measurement group_id="O3" value="3.6" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Who Had at Least 1 Adverse Event in Any Category</title>
        <description>AE = adverse event, bid = twice daily, IP = investigational product, qd = once daily, SAE = serious adverse event</description>
        <time_frame>Entry in extension to end of study (variable duration; maximum 109 weeks)</time_frame>
        <population>The full analysis set includes those patients who received at least 1 dose of investigational product, and were summarised according to treatment first received in this study (intention-to-treat principle).</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 100 mg Bid</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 150 mg qd</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O3">
            <title>Fostamatinib 100 mg qd</title>
            <description>Oral treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Had at Least 1 Adverse Event in Any Category</title>
          <description>AE = adverse event, bid = twice daily, IP = investigational product, qd = once daily, SAE = serious adverse event</description>
          <population>The full analysis set includes those patients who received at least 1 dose of investigational product, and were summarised according to treatment first received in this study (intention-to-treat principle).</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1343"/>
                <count group_id="O2" value="357"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4"/>
                    <measurement group_id="O2" value="70.3"/>
                    <measurement group_id="O3" value="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE with outcome of death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE (including events with outcome of death)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="8.7"/>
                    <measurement group_id="O3" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE leading to discontinuation of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="5.9"/>
                    <measurement group_id="O3" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean mTSS Score</title>
        <description>mTSS: modified total sharp score, a measure of structural progression based upon X-rays. Hand and foot joints are scored for erosions and joint space narrowing and the results summed to give a value between 0 and 488. A higher value represents more serious progression of the disease. Number of participants are those with data at entry to this study (Week 0). As no imputation was applied, the numbers at subsequent visits are lower. bid = twice daily, N/A = not applicable, qd = once daily</description>
        <time_frame>Weeks 0 and 52</time_frame>
        <population>The full analysis set includes those patients who received at least 1 dose of investigational product, and were summarised according to treatment first received in this study (intention-to-treat principle).</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 100 mg Bid</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 150 mg qd</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O3">
            <title>Fostamatinib 100 mg qd</title>
            <description>Oral treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Mean mTSS Score</title>
          <description>mTSS: modified total sharp score, a measure of structural progression based upon X-rays. Hand and foot joints are scored for erosions and joint space narrowing and the results summed to give a value between 0 and 488. A higher value represents more serious progression of the disease. Number of participants are those with data at entry to this study (Week 0). As no imputation was applied, the numbers at subsequent visits are lower. bid = twice daily, N/A = not applicable, qd = once daily</description>
          <population>The full analysis set includes those patients who received at least 1 dose of investigational product, and were summarised according to treatment first received in this study (intention-to-treat principle).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=480, 73, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" spread="47.73"/>
                    <measurement group_id="O2" value="22.2" spread="32.89"/>
                    <measurement group_id="O3" value="20.8" spread="46.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=223, 1, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="46.83"/>
                    <measurement group_id="O2" value="0.5">Measures of spread are not defined for treatment groups containing a single patient.</measurement>
                    <measurement group_id="O3" value="37.3" spread="67.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean HAQ-DI Score</title>
        <description>HAQ-DI: Health Assessment Questionnaire - Disability Index, a measure of physical function. The HAQ-DI score is then calculated by summing the category scores from 8 sub-categories (ie, scores for patient ability in dressing and grooming, rising, eating, walking, hygiene, reach, grip and common daily activities) and dividing by the number of categories completed. The HAQ-DI score takes values between 0 and 3, with a higher score indicating greater disability. Number of participants are those with data at entry to this study (Week 0). As no imputation was applied, the numbers at subsequent visits are lower. bid = twice daily, qd = once daily</description>
        <time_frame>Weeks 0, 12, 24, 36 and 52</time_frame>
        <population>The full analysis set includes those patients who received at least 1 dose of investigational product, and were summarised according to treatment first received in this study (intention-to-treat principle).</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 100 mg Bid</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 150 mg qd</title>
            <description>Oral treatment</description>
          </group>
          <group group_id="O3">
            <title>Fostamatinib 100 mg qd</title>
            <description>Oral treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Mean HAQ-DI Score</title>
          <description>HAQ-DI: Health Assessment Questionnaire - Disability Index, a measure of physical function. The HAQ-DI score is then calculated by summing the category scores from 8 sub-categories (ie, scores for patient ability in dressing and grooming, rising, eating, walking, hygiene, reach, grip and common daily activities) and dividing by the number of categories completed. The HAQ-DI score takes values between 0 and 3, with a higher score indicating greater disability. Number of participants are those with data at entry to this study (Week 0). As no imputation was applied, the numbers at subsequent visits are lower. bid = twice daily, qd = once daily</description>
          <population>The full analysis set includes those patients who received at least 1 dose of investigational product, and were summarised according to treatment first received in this study (intention-to-treat principle).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1271"/>
                <count group_id="O2" value="342"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=1271, 342, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.69"/>
                    <measurement group_id="O2" value="1.0" spread="0.64"/>
                    <measurement group_id="O3" value="1.0" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=1061, 298, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.68"/>
                    <measurement group_id="O2" value="1.0" spread="0.63"/>
                    <measurement group_id="O3" value="1.0" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=817, 238, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.68"/>
                    <measurement group_id="O2" value="1.0" spread="0.67"/>
                    <measurement group_id="O3" value="0.9" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=587, 149, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.67"/>
                    <measurement group_id="O2" value="1.0" spread="0.65"/>
                    <measurement group_id="O3" value="1.1" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=296, 28, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.68"/>
                    <measurement group_id="O2" value="1.1" spread="0.64"/>
                    <measurement group_id="O3" value="1.0" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>FOSTA 100 MG BID</title>
        </group>
        <group group_id="E2">
          <title>FOSTA 100 MG QD</title>
        </group>
        <group group_id="E3">
          <title>FOSTA 150 MG QD</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="1343"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>SPLENIC INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ACUTE ABDOMEN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>BARRETT'S OESOPHAGUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>COLITIS MICROSCOPIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>COLONIC STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ILEITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ACHALASIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PANCREATIC PSEUDOCYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS CHRONIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>GALLBLADDER POLYP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>POST CHOLECYSTECTOMY SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>FOOD ALLERGY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>BACTERIAL PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISCITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>LIVER ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>OTITIS EXTERNA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PANCREATITIS VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PNEUMONIA VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>WOUND SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PATELLA FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ULNA FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>HIP DEFORMITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DISPLACEMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>OSTEITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PATHOLOGICAL FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>SJOGREN'S SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>SPONDYLOLISTHESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>SYNOVITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>BENIGN NEOPLASM OF PROSTATE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>BENIGN SOFT TISSUE NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>COLORECTAL CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>LIPOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PANCREATIC NEUROENDOCRINE TUMOUR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>RENAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>VAGINAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC STROKE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIC COMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>LUMBAR RADICULOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>RADICULITIS LUMBOSACRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>TENSION HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>VITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ADJUSTMENT DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ALCOHOL ABUSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>URINARY BLADDER POLYP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ADENOMYOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>HYPERVENTILATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DIGITAL ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ERYTHEMA MULTIFORME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>TOXIC EPIDERMAL NECROLYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1343"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>AORTIC THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1343"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="466" subjects_at_risk="1343"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="268" subjects_affected="202" subjects_at_risk="1343"/>
                <counts group_id="E2" events="40" subjects_affected="28" subjects_at_risk="212"/>
                <counts group_id="E3" events="61" subjects_affected="43" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="102" subjects_affected="86" subjects_at_risk="1343"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="212"/>
                <counts group_id="E3" events="31" subjects_affected="28" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" events="155" subjects_affected="116" subjects_at_risk="1343"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="212"/>
                <counts group_id="E3" events="35" subjects_affected="30" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="197" subjects_affected="166" subjects_at_risk="1343"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="212"/>
                <counts group_id="E3" events="23" subjects_affected="20" subjects_at_risk="357"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restriction on the PI is that the sponsor can review and comment on results communications prior to publication. Sponsor will be allowed a review period of at least 60 days from submission but can request that publication be delayed for a period up to 6 months. Any reasonable comments made by the sponsor will be incorporated by the PI into the publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dave Goldstraw</name_or_title>
      <organization>AstraZeneca Pharmaceuticals</organization>
      <phone>+44 (0)1625 512415</phone>
      <email>dave.goldstraw@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

